Apollomics Inc. Warrant - APLMW STOCK NEWS

Apollomics (Nasdaq: APLM) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation on December 10, 2024, that its Class A Ordinary Shares maintained a closing bid price of $1.00 or higher for ten consecutive business days from November 25 to December 9, 2024. This development ensures the continued listing of Apollomics' shares on the Nasdaq Capital Market under the symbol 'APLM'. The matter is now considered closed.

Apollomics (Nasdaq: APLM) announced a 1-for-100 reverse share split of its class A ordinary shares, effective November 25, 2024. The split was approved by shareholders at the Extraordinary General Meeting on November 14, 2024. The company's shares will continue trading under 'APLM' with a new CUSIP number G0411D123. The authorized share capital will increase to 130,000,000 shares. As part of the split, warrant exercise prices will be adjusted, with public warrants' exercise price increasing to $1,150.00 from $11.50. No fractional shares will be issued.

Apollomics Inc. (Nasdaq: APLM) presented data on vebreltinib for non-small cell lung cancer (NSCLC) with METex14 skipping mutations at the ESMO Congress 2024. Key findings include:

1. Efficacy in both treatment-naïve and previously treated patients:
- Treatment-naïve: 66.7% overall response rate (ORR), 17.3 months median duration of response (DOR), 13.8 months median progression-free survival (PFS)
- Previously treated: 61.1% ORR, 16.7 months median DOR, 7.4 months median PFS

2. Efficacy regardless of MET gene copy number (GCN):
- GCN<4: 67.8% ORR
- GCN<6: 69.2% ORR
- GCN>4: 100% ORR (5/5 patients)

3. Safety profile: 48.1% of patients experienced grade 3 or higher treatment-related adverse events, with edema being most common (16.7%). No deaths were reported due to treatment-emergent adverse events.

Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024, both virtually and in-person at the Lotte New York Palace Hotel in New York, NY.

Key details of Apollomics' participation include:

• An on-demand company presentation available from September 9, 2024, at 7:00 am ET
• Presenters: Guo-Liang Yu, PhD (Chairman and CEO) and Matthew Plunkett, PhD (CFO)
• Management will be available for virtual one-on-one meetings
• The presentation will be accessible on the company's website

Apollomics focuses on developing oncology drug candidates for difficult-to-treat and treatment-resistant cancers.

Apollomics Inc. (Nasdaq: APLM) reported its first half 2024 financial results and clinical progress for vebreltinib. Key highlights include:

1. Promising preliminary results from the vebreltinib program for tumors with Met dysregulation, including non-CNS MET fusion tumors and NSCLC with MET amplification.

2. Cash position of $25.9 million as of June 30, 2024, with runway into Q3 2025.

3. R&D expenses of $16.9 million and G&A expenses of $10.2 million for H1 2024.

4. Net loss of $(35.2) million, or $(0.38) per share, including a $10 million impairment loss for uproleselan.

5. Strategic focus on vebreltinib for NSCLC patients with Met Amplification.

6. Raised $5.8 million in a PIPE financing in May 2024.

Apollomics Inc. (Nasdaq: APLM) announced positive preliminary data from its Phase 2 SPARTA trial of vebreltinib in patients with non-CNS MET fusion solid tumors. The study showed a 43% overall response rate, with six confirmed responses out of 14 patients. Key highlights include:

- One complete response in metastatic non-small cell lung cancer (NSCLC)
- Five partial responses across NSCLC, pancreatic cancer, and intrahepatic bile duct cancer
- Median overall survival of 12.4 months
- Median progression-free survival of 4.5 months
- Median duration of response of 5.6 months
- Longest ongoing response of 18 months

The company believes these results support vebreltinib's potential as a targeted therapy for tumors with MET alterations, which occur in 0.1-0.3% of solid tumors.

Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company focusing on oncology drug candidates for difficult-to-treat and treatment-resistant cancers, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 13-15, 2024, in Boston, MA.

Key details of Apollomics' presentation:

• Date and Time: Tuesday, August 14, 2024, at 9:30 am ET
• Location: InterContinental Boston Hotel
• Presenter: Matthew Plunkett, PhD, Chief Financial Officer

The company management will be available for one-on-one meetings during the conference. Interested investors can contact their Canaccord Genuity representative to schedule meetings. A webcast link for the presentation will be available on the company's website under the Investors section on the Events page.

Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement. The company now has until January 13, 2025 to meet the $1.00 per share minimum bid price for its Ordinary Shares. This extension follows a previous notice of non-compliance received on January 16, 2024.

To regain compliance, Apollomics must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days before the deadline. If unsuccessful, the company may face delisting, with an option to appeal to a Nasdaq Hearings Panel. Apollomics is actively monitoring its stock price and exploring options to meet the requirement, though success is not guaranteed.

Apollomics (Nasdaq: APLM) announced a revised strategic focus on the clinical development of vebreltinib for NSCLC patients with Met Amplification mutations and significant changes in its executive leadership. The SPARTA Phase 2 trial will concentrate on this high-need patient population. Co-founder and President Sanjeev Redkar, Ph.D., and Chief Medical Officer Peony Yu, M.D., will transition to consulting roles in August. These changes are part of a broader cost-reduction strategy expected to cut operating expenses by over 50% and extend funding until Q3 2025.

Apollomics aims to generate additional clinical data to support regulatory submissions, with updates anticipated in 2024 and 2025. The departures of key executives are aligned with the company's resource needs and focus on maximizing the efficient use of capital.